Pharmacology of insulin detemir
Related Experiment Video
Updated: Jul 11, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
1Diabetes Research, Novo Nordisk A/S, Bagsvaerd, Copenhagen, Denmark. pkur@novonordisk.com
Abstract:
Insulin detemir (Levemir [Novo Nordisk A/S, Bagsvaerd, Denmark]) is a soluble, long-acting basal insulin analog. It differs from human insulin in that the amino acid threonine in position B30 has been removed and a 14-carbon fatty acid (myristic acid) has been acylated to lysine at B29. This modification increases self-association and enables albumin binding of insulin detemir. In this manuscript, the unique molecular properties and the resulting pharmacodynamics of insulin detemir are reviewed. The protracted duration of action, smooth activity profile, and low intrapatient variability of insulin detemir are presented as properties that may potentially help patients maximize glycemic control and minimize the long-term complications of diabetes.
Related Concept Videos
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into rapid-acting...
Insulin: The Receptor and Signaling Pathways
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Oral Hypoglycemic Agents: Glinides
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are co-secreted in...

